Drugs Made in America Acquisition Ii CORP 8-K filings

Drugs Made In America Acquisition II Corp. has finalized compensation agreements for its CEO and CFO, including deferred cash payments and performance-based equity grants.

Drugs Made In America Acquisition II Corp. has finalized a $1.4 million financing agreement with Tal Alpha Yezum Vekidum Asakim (2003) LTD, including an interim convertible note of $300,000.

Drugs Made In America Acquisition II Corp. secured a $150,000 bridge loan from Alpha Multi Family Office, part of a larger $1.4 million convertible note financing plan to support its business combination efforts.

Drugs Made In America Acquisition II Corp. confirmed its trust account balance remains intact following previously reported improper sponsor withdrawals from its working capital.

Drugs Made In America Acquisition II Corp. announced the resignation of its CEO and Executive Chair following the discovery of significant unauthorized withdrawals and overpayments by its sponsor.

Drugs Made In America Acquisition II Corp. announced the resignation of its CFO, Glenn Worman, and the appointment of Saleem Elmasri as his successor.

Drugs Made In America Acquisition II Corp. successfully closed its initial public offering of $500 million, placing proceeds into a trust account for a future pharmaceutical business combination.

Drugs Made In America Acquisition II Corp., a SPAC focused on the pharmaceutical industry, announced the pricing and closing of its $500 million initial public offering and a concurrent $12 million private placement.